Depo-Provera Lawsuit

About Depo-Provera

Depo-Provera is a hormonal contraceptive injection containing medroxyprogesterone acetate (DMPA), a synthetic progestin. FDA-approved in 1992, it has become one of the most popular forms of birth control in the United States and worldwide, with millions of women relying on it for contraception. The injection is administered four times per year, with each injection providing protection against pregnancy for approximately 12 weeks.

The medication works by preventing ovulation and thickening cervical mucus, making it over 99% effective at preventing pregnancy when used consistently. Its convenience — requiring only four injections annually rather than daily pill administration — has made it an attractive option for women seeking long-acting reversible contraception. Healthcare providers have widely prescribed Depo-Provera for decades, with minimal contraindications mentioned in standard prescribing information.

Depo-Provera is manufactured by Pfizer, which acquired the rights through previous acquisitions of Upjohn and Pharmacia. The medication has been marketed aggressively, particularly in the United States and Europe, with promotional campaigns emphasizing its safety and effectiveness as a reliable birth control method.

Despite its widespread use and general acceptance, recent research has raised concerns about potential serious side effects associated with prolonged hormonal exposure through Depo-Provera use, particularly the increased risk of benign brain tumors known as meningiomas.

Health Risks & Brain Tumor Link

Recent scientific research has identified a concerning link between extended Depo-Provera use and the development of meningioma, a benign but potentially serious brain tumor. While meningiomas are typically non-cancerous, they can cause significant neurological complications and require surgical intervention.

A significant 2024 French regulatory study found that women using Depo-Provera for extended periods had an increased risk of developing meningioma. The French National Agency for the Safety of Medicines and Health Products (ANSM) conducted a comprehensive analysis and concluded that prolonged use of DMPA injections was associated with approximately a 2-3 fold increased risk of meningioma diagnosis.

The mechanism behind this increased risk appears to be related to how synthetic progestins like DMPA interact with meningioma cells. Meningiomas express high levels of progesterone receptors on their cell surfaces. The synthetic progestin in Depo-Provera may stimulate growth of these tumor cells through receptor activation, though the tumor itself remains benign (non-cancerous).

People at particular risk include women who used Depo-Provera for more than 5 years, and especially those who used it continuously from their 20s through their 40s. Women are significantly more likely to develop meningiomas than men, and hormonal contraceptives are believed to play a role in this gender disparity.

Settlements & Verdicts

Depo-Provera litigation is in its early stages, with cases beginning to emerge primarily in 2024 and 2025 following the French regulatory findings. Unlike the Roundup litigation, there are currently no major settlements or jury verdicts in Depo-Provera cases, as the litigation is still developing.

As this litigation develops, settlement amounts will likely be determined based on factors such as the severity and extent of the meningioma, whether surgery was required, neurological complications, medical expenses, lost wages, and pain and suffering. A qualified attorney can assess the potential value of your specific case during a free review.

Scientific Evidence

The scientific basis for the Depo-Provera-meningioma link is substantial and growing, with multiple studies and regulatory agencies now recognizing this relationship.

The most significant finding came in 2024 when the French National Agency for the Safety of Medicines and Health Products (ANSM) published results of a comprehensive study examining the association between medroxyprogesterone acetate (DMPA) use and meningioma risk. The ANSM concluded that women using DMPA had a 2-3 fold increased risk of being diagnosed with a meningioma compared to non-users. The risk appeared to increase with duration of use, and the elevated risk persisted even after discontinuation of the medication.

This finding was further supported by peer-reviewed research published in the British Medical Journal (BMJ) in 2024. The study examined data across multiple countries and found consistent evidence of increased meningioma incidence associated with hormonal contraceptives containing progestins, particularly with DMPA products like Depo-Provera. The researchers noted that the biological plausibility of this association is strong — meningiomas express high levels of progesterone receptors, and synthetic progestins can stimulate cellular proliferation through these receptors.

Medical literature has documented that meningiomas are hormone-sensitive tumors. Studies of receptor expression in meningioma tissue samples have consistently shown that progesterone receptors are overexpressed in these tumors compared to normal brain tissue. This molecular evidence supports the biological mechanism by which synthetic progestins like those in Depo-Provera could promote meningioma growth and development.

How to File a Depo-Provera Claim

Filing a Depo-Provera lawsuit through LegalCove is straightforward and costs nothing upfront. Attorneys in our network work on a contingency fee basis, meaning you only pay if your case results in compensation.